Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE)
Source: View publication →
The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly improved overall survival and radiographic progression-free survival in men with newly diagnosed, high-risk metastatic castration-sensitive prostate cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
The LATITUDE trial, published concurrently with the STAMPEDE abiraterone data, catalyzed a paradigm shift in the management of metastatic hormone-sensitive prostate cancer. It demonstrated that upfront treatment intensification with a next-generation androgen receptor axis-targeted agent (abiraterone) alongside ADT yields profound survival benefits, establishing a new standard of care over the traditional use of ADT alone.
Historical Context
For decades, androgen-deprivation therapy (ADT) alone was the standard frontline treatment for metastatic prostate cancer. In 2015, the CHAARTED and STAMPEDE trials demonstrated that adding docetaxel chemotherapy to ADT improved survival. The 2017 LATITUDE trial built upon this momentum by evaluating whether an alternative approach—maximum androgen blockade using the CYP17 inhibitor abiraterone acetate—could achieve similar or superior outcomes without the toxicities associated with cytotoxic chemotherapy. The overwhelmingly positive results transformed the therapeutic landscape, establishing early AR-axis inhibition as a core pillar of mCSPC management.
Guided Discussion
High-yield insights from every perspective
Abiraterone is administered with prednisone in the LATITUDE trial. Based on the mechanism of action of abiraterone, why is the addition of a corticosteroid physiologically necessary?
Key Response
Abiraterone inhibits CYP17A1, blocking both cortisol and androgen synthesis. The resulting drop in cortisol removes negative feedback on ACTH production from the pituitary. High ACTH drives the accumulation of mineralocorticoid precursors upstream of the block, leading to hypertension, hypokalemia, and fluid retention. Co-administering prednisone replaces glucocorticoids, suppresses ACTH, and prevents this mineralocorticoid excess syndrome.
The LATITUDE trial evaluated patients with high-risk metastatic castration-sensitive prostate cancer. What were the specific criteria used to define high-risk in this study, and how do you use this in clinical practice to identify patients who need therapy intensification beyond ADT alone?
Key Response
High-risk was defined as having at least two of three factors: Gleason score 8 or higher, presence of 3 or more lesions on a bone scan, and presence of measurable visceral metastasis. Recognizing these precise criteria is crucial for residents to accurately stratify patients and justify the early intensification of ADT with abiraterone to maximize overall survival.
Both the LATITUDE trial (using abiraterone) and the CHAARTED trial (using docetaxel) demonstrated significant survival benefits when added to ADT for newly diagnosed metastatic prostate cancer. How do the high-risk criteria of LATITUDE overlap with the high-volume criteria of CHAARTED, and what patient-specific factors drive your choice between these two agents?
Key Response
CHAARTED defined high-volume as 4 or more bone metastases (with at least 1 outside the spine/pelvis) or visceral metastases. This heavily overlaps with LATITUDEs high-risk criteria, though LATITUDE includes Gleason score. Since no prospective head-to-head trials show definitive superiority of one over the other, the choice is driven by patient fitness for chemotherapy, comorbidities (e.g., poorly controlled diabetes or heart failure favor docetaxel to avoid steroid/mineralocorticoid effects), financial toxicity, and patient preference.
With the shift of abiraterone into the upfront hormone-sensitive setting as proven by LATITUDE, how does this early exposure alter tumor biology, and what are the practice-changing implications for your sequencing strategy when patients eventually progress to castration-resistant prostate cancer?
Key Response
Early use of a potent androgen receptor pathway inhibitor (ARPI) like abiraterone exerts selective pressure that alters tumor biology, often promoting earlier emergence of AR-V7 splice variants or neuroendocrine differentiation. As a result, sequencing a second ARPI (like enzalutamide) in the castration-resistant setting yields very poor response rates. The practice-changing implication is that upon progression after LATITUDE-style upfront therapy, clinicians must rapidly pivot to alternative mechanisms, such as docetaxel/cabazitaxel, PARP inhibitors for HRR mutations, or Lu-177 PSMA radioligand therapy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The LATITUDE trial utilized co-primary endpoints of overall survival and radiographic progression-free survival. From a statistical methodology perspective, how does utilizing co-primary endpoints impact the alpha-spending function, and what are the strategic advantages of this design in long-term oncology trials?
Key Response
Using co-primary endpoints requires partitioning the overall type I error rate (alpha) between the two outcomes to rigorously control the family-wise error rate. The strategic advantage in prostate cancer trials is that radiographic progression-free survival provides an earlier, highly sensitive surrogate read-out of efficacy, allowing for faster trial completion and potential crossover, while overall survival remains the gold-standard definitive endpoint that will mature later due to the long natural history of the disease and effective subsequent therapies.
As a reviewer evaluating the LATITUDE manuscript, how do you appraise the studys control arm of ADT plus placebos given the timeline of its design, and does the lack of a docetaxel-containing comparator arm threaten the external validity of the results for a contemporary audience?
Key Response
When LATITUDE was designed in 2013, ADT alone was the standard of care. However, by the time of its publication in 2017, the CHAARTED and STAMPEDE trials had already established ADT plus docetaxel as a new standard for high-volume or high-risk disease. A stringent reviewer would flag that comparing abiraterone to ADT alone limits external validity for contemporary practice, as it leaves clinicians without direct prospective data comparing the new intervention against the contemporary active standard of chemotherapy, forcing reliance on indirect network meta-analyses.
Following the robust overall survival data from LATITUDE and STAMPEDE, how should clinical practice guidelines formally update the standard of care for mCSPC, and what nuances regarding risk stratification must be explicitly addressed in the recommendation algorithms?
Key Response
Guidelines from the NCCN, AUA, and EAU must update their pathways to reflect a Category 1 recommendation for adding abiraterone and prednisone to ADT in patients with mCSPC. The committee must explicitly highlight that while ADT alone is no longer the standard for robust patients, the LATITUDE data strictly applies to the high-risk subgroup. Therefore, algorithms must clearly define high-risk versus low-risk and high-volume versus low-volume states to help clinicians appropriately choose between abiraterone, docetaxel, other ARPIs, or radiation to the primary tumor based on integrated evidence.
Clinical Landscape
Noteworthy Related Trials
CHAARTED Trial
Tested
Docetaxel + ADT
Population
Metastatic hormone-sensitive prostate cancer
Comparator
ADT alone
Endpoint
Overall survival
STAMPEDE Trial (Abiraterone Arm)
Tested
Abiraterone acetate + prednisolone + ADT
Population
Locally advanced or metastatic prostate cancer starting ADT
Comparator
ADT alone
Endpoint
Overall survival
TITAN Trial
Tested
Apalutamide + ADT
Population
Metastatic castration-sensitive prostate cancer
Comparator
Placebo + ADT
Endpoint
Radiographic progression-free survival and overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis